Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 2/2022

Open Access 01-06-2022 | Breast Cancer | Epidemiology

Breast cancer incidence and survival in Scotland by socio-economic deprivation and tumour subtype

Authors: Ines Mesa-Eguiagaray, Sarah H. Wild, Sheila M. Bird, Linda J. Williams, David H. Brewster, Peter S. Hall, Jonine D. Figueroa

Published in: Breast Cancer Research and Treatment | Issue 2/2022

Login to get access

Abstract

Background

Women from socio-economically deprived areas are less likely to develop and then to survive breast cancer (BC). Whether associations between deprivation and BC incidence and survival differ by tumour molecular subtypes and mode of detection in Scotland are unknown.

Methods

Data consisted of 62,378 women diagnosed with invasive BC between 2000 and 2016 in Scotland. Incidence rates and time trends were calculated for oestrogen receptor positive (ER+) and negative (ER−) tumours and stratified by the Scottish Index of Multiple Deprivation (SIMD) quintiles and screening status. SIMD is an area-based measure derived across seven domains: income, employment, education, health, access to services, crime and housing. We calculated adjusted hazard ratios (aHR [95% confidence intervals]) for BC death by immunohistochemical surrogates of molecular subtypes for the most versus the least deprived quintile. We adjusted for mode of detection and other confounders.

Results

In Scotland, screen-detected ER+tumour incidence increased over time, particularly in the least deprived quintile [Average Annual Percentage Change (AAPC) = 2.9% with 95% CI from 1.2 to 4.7]. No marked differences were observed for non-screen-detected ER+tumours or ER− tumours by deprivation. BC mortality was higher in the most compared to the least deprived quintile irrespective of ER status (aHR = 1.29 [1.18, 1.41] for ER+ and 1.27 [1.09, 1.47] for ER− tumours). However, deprivation was associated with significantly higher mortality for luminal A and HER2−enriched tumours (aHR = 1.46 [1.13, 1.88] and 2.10 [1.23, 3.59] respectively) but weaker associations for luminal B and TNBC tumours that were not statistically significant.

Conclusions

Deprivation is associated with differential BC incidence trends for screen-detected ER+tumours and with higher mortality for select tumour subtypes. Future efforts should evaluate factors that might be associated with reduced survival in deprived populations and monitor progress stratified by tumour subtypes and mode of detection.
Appendix
Available only for authorised users
Literature
1.
Independent UK Panel on Breast Cancer Screening (2012) The benefits and harms of breast cancer screening: an independent review. Lancet 380(9855):1778–1786CrossRef
2.
Macmillan Cancer Support-NHS (2017) Deprivation and Survival from Breast Cancer in Scotland
3.
Jang B-S, Chang JH (2019) Socioeconomic status and survival outcomes in elderly cancer patients: a national health insurance service-elderly sample cohort study. Cancer Med 8(7):3604–3613PubMedPubMedCentralCrossRef
4.
Pruitt SL et al (2009) Association of area socioeconomic status and breast, cervical, and colorectal cancer screening: a systematic review. Cancer Epidemiol Biomark Prev 18(10):2579CrossRef
5.
6.
Woods LM et al (2016) Impact of deprivation on breast cancer survival among women eligible for mammographic screening in the West Midlands (UK) and New South Wales (Australia): women diagnosed 1997–2006. Int J Cancer 138(10):2396–2403PubMedPubMedCentralCrossRef
7.
Mullooly M et al (2017) Divergent oestrogen receptor-specific breast cancer trends in Ireland (2004–2013): amassing data from independent Western populations provide etiologic clues. Eur J Cancer 86:326–333PubMedPubMedCentralCrossRef
8.
Engstrøm MJ et al (2013) Molecular subtypes, histopathological grade and survival in a historic cohort of breast cancer patients. Breast Cancer Res Treat 140(3):463–473PubMedPubMedCentralCrossRef
9.
10.
Howlader N et al (2018) Differences in breast cancer survival by molecular subtypes in the United States. Cancer Epidemiol Biomark Prev 27(6):619–626CrossRef
11.
Anderson WF, Katki HA, Rosenberg PS (2011) Incidence of breast cancer in the United States: current and future trends. J Natl Cancer Inst 103(18):1397–1402PubMedPubMedCentralCrossRef
12.
Johansson ALV et al (2019) Breast cancER−specific survival by clinical subtype after 7 years follow-up of young and elderly women in a nationwide cohort. Int J Cancer 144(6):1251–1261PubMedCrossRef
13.
14.
Ellis L et al (2018) Racial and ethnic disparities in cancer survival: the contribution of tumor, sociodemographic, institutional, and neighborhood characteristics. J Clin Oncol 36(1):25–33PubMedCrossRef
15.
Lundqvist A et al (2016) Socioeconomic inequalities in breast cancer incidence and mortality in Europe—a systematic review and meta-analysis. Eur J Public Health 26(5):804–813PubMedPubMedCentralCrossRef
16.
Lian M et al (2014) Neighborhood socioeconomic deprivation, tumor subtypes, and causes of death after non-metastatic invasive breast cancer diagnosis: a multilevel competing-risk analysis. Breast Cancer Res Treat 147(3):661–670PubMedPubMedCentralCrossRef
17.
Parise CA et al (2009) Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999–2004. Breast J 15(6):593–602PubMedCrossRef
18.
Bauer KR et al (2007) Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2−negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer 109(9):1721–1728PubMedCrossRef
19.
Bastiaannet E et al (2011) Socioeconomic differences in survival among breast cancer patients in the Netherlands not explained by tumor size. Breast Cancer Res Treat 127(3):721–727PubMedCrossRef
20.
Cross CK, Harris J, Recht A (2002) Race, socioeconomic status, and breast carcinoma in the U.S: what have we learned from clinical studies. Cancer 95(9):1988–1999PubMedCrossRef
21.
Rutqvist LE, Bern A (2006) Socioeconomic gradients in clinical stage at presentation and survival among breast cancer patients in the Stockholm area 1977–1997. Int J Cancer 119(6):1433–1439PubMedCrossRef
22.
Thomson CS et al (2001) Prognostic factors in women with breast cancer: distribution by socioeconomic status and effect on differences in survival. J Epidemiol Community Health 55(5):308–315PubMedPubMedCentralCrossRef
23.
Vona-Davis L, Rose DP (2009) The influence of socioeconomic disparities on breast cancer tumor biology and prognosis: a review. J Womens Health 18(6):883–893CrossRef
24.
Amirikia KC et al (2011) Higher population-based incidence rates of triple-negative breast cancer among young African-American women : Implications for breast cancer screening recommendations. Cancer 117(12):2747–2753PubMedCrossRef
25.
Carey LA et al (2006) Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295(21):2492–2502PubMedCrossRef
26.
27.
Gluz O et al (2009) Triple-negative breast cancer–current status and future directions. Ann Oncol 20(12):1913–1927PubMedCrossRef
28.
Mesa-Eguiagaray I et al (2020) Distinct temporal trends in breast cancer incidence from 1997 to 2016 by molecular subtypes: a population-based study of Scottish cancer registry data. Br J Cancer 123(5):852–859PubMedPubMedCentralCrossRef
29.
Brewster DH, Stockton DL (2008) Ascertainment of breast cancer by the Scottish Cancer Registry: an assessment based on comparison with five independent breast cancer trials databases. Breast 17(1):104–106PubMedCrossRef
30.
31.
32.
Goldhirsch A et al (2011) Strategies for subtypes–dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 22(8):1736–1747PubMedPubMedCentralCrossRef
33.
34.
Kendrick S, Clarke J (1993) The Scottish Record Linkage System. Health Bull 51(2):72–79
35.
Public Health Scotland. Scottish Cancer Registry- cancer metadata. Data and Intelligence 2020. Cited 2020
36.
Skyrud KD, Bray F, Møller B (2014) A comparison of relative and cause-specific survival by cancer site, age and time since diagnosis. Int J Cancer 135(1):196–203PubMedCrossRef
37.
38.
National Records of Scotland (2019) Mid-2018 Population Estimates for Scotland: Methodology Guide
39.
40.
Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53(282):457–481CrossRef
41.
NHS Scotland (2016) Breast cancer clinical quality performance indicators, Scottish cancer taskforce national cancer quality steering group, Editor
42.
Cox DR (1972) Regression models and life-tables. J R Stat Soc Ser B (Methodological) 34(2):187–220
43.
Charlson ME et al (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40(5):373–383PubMedCrossRef
44.
45.
Harper S et al (2009) Trends in area-socioeconomic and race-ethnic disparities in breast cancer incidence, stage at diagnosis, screening, mortality, and survival among women ages 50 years and over (1987–2005). Cancer Epidemiol Prevent Biomark 18(1):121–131CrossRef
46.
Sprague BL et al (2011) Socioeconomic status and survival after an invasive breast cancer diagnosis. Cancer 117(7):1542–1551PubMedCrossRef
47.
Cheong CK et al. (2020) The Scottish Health Survey 2018 edition; amended in February 2020: Volume 1, Main report
48.
49.
50.
Public Health Information for Scotland (2022) Physical activity: adults, in Behaviour-Physical Activity
51.
52.
Stockton D, McCann J (2001) Cancer registries in monitoring, evaluating and planning breast cancer screening programmes. Evaluation and Monitoring of Screening Programmes. Office for Official Publications of the European Communities, Luxembourg, pp 181–194
53.
Berry DA et al (2009) Flawed inferences about screening mammography’s benefit based on observational data. J Clin Oncol 27(4):639–640PubMedCrossRef
54.
Tunstall R, Lupton R (2003) Is targeting deprived areas an effective means to reach poor people? An assessment of one rationale for Area-Based Funding Programmes, CASE/70. London School of Economics and Political Science, London
55.
Robson B et al (2001) Deprivation in London: an alternative to IMD 2000. University of Manchester, Manchester
56.
Afshar N, English DR, Milne RL (2021) Factors explaining socio-economic inequalities in cancer survival: a systematic review. Cancer Control 28:10732748211011956PubMedPubMedCentralCrossRef
Metadata
Title
Breast cancer incidence and survival in Scotland by socio-economic deprivation and tumour subtype
Authors
Ines Mesa-Eguiagaray
Sarah H. Wild
Sheila M. Bird
Linda J. Williams
David H. Brewster
Peter S. Hall
Jonine D. Figueroa
Publication date
01-06-2022
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 2/2022
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-022-06632-1

Other articles of this Issue 2/2022

Breast Cancer Research and Treatment 2/2022 Go to the issue

Epidemiology

Impact of genomic assays on treatment and outcomes in locally advanced breast cancer

Epidemiology

Single-nucleotide polymorphisms and the effectiveness of taxane-based chemotherapy in premenopausal breast cancer: a population-based cohort study in Denmark

Epidemiology

Insulin resistance and weight gain in women treated for early stage breast cancer

Clinical trial

Accuracy of the Breast Cancer Surveillance Consortium Model Among Women with LCIS

Epidemiology

Breast reconstruction and quality of life five years after cancer diagnosis: VICAN French National cohort

Clinical trial

The risk of PD-L1 expression misclassification in triple-negative breast cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits